Ranbaxy may have to pay huge fine, again
Ranbaxy Laboratories, set to be merged with Sun Pharmaceutical Industries, might again have to pay a hefty penalty to the US authorities for alleged violations at its Toansa factory in Punjab. The facility
Ranbaxy Pharmaceuticals
-
US not to buy Ranbaxy AIDS drugs
Bloomberg / Mumbai September 26, 2008, 0:14 IST American relief programme suspends funding for three generic medicines. AIDS drugs made by Ranbaxy Laboratories won't be purchased under an American programme to supply medicines to developing countries after the US cited the company for violations in two of its plants.
-
US ban on Ranbaxy drugs & India pharma
D G Shah Secretary General IPA* A sense of doom is not at all warranted THE recent FDA action is a warning for several other companies that are already in the US market or intend to enter it in the near future. Just as they had learnt to emulate the success of the pioneering efforts of Ranbaxy, they will learn the hard lessons from the recent experience of Ranbaxy.
-
US panel asks Rice to furnish details of AIDS drugs supplied by Ranbaxy
Nina Mehta MUMBAI
-
Daiichi to pay interest for open offer delay
Daiichi Sankyo has said that there are procedural delays in completing the open offer for acquiring an additional 20% equity of Ranbaxy. The delay pertains to payments to shareholders who have subscribed to the Japanese company's open offer for acquiring an additional 20% equity of Ranbaxy.
-
U.S. bans Ranbaxy drugs
THE U.S. BAN ON some medicines made by India's largest pharmaceutical company adds a black mark against India's booming drug and drug-testing industries, which already have been under pressure over the country's lax monitoring of drug safety.
-
Ranbaxy tanks on FDA ruling
Bs Reporter / New Delhi/tokyo September 18, 2008, 0:30 IST
-
U.S. blocks 30 Ranbaxy drugs
Lapses on record-keeping Affects numerous, widely-used medications Preventive action to protect quality of drugs
-
Peace on patents to boost Ranbaxy
Joe C Mathew / New Delhi August 27, 2008, 0:39 IST Firm reaches out-of-court agreement on 5 of 19 patent challenges in the US. Ranbaxy Laboratories, India's largest pharmaceutical drug firm by sales, expects its recent patent litigation settlements to add significantly to its revenues as well as net profit. The numbers could run into billions of dollars, sources familiar with the company's strategy said. The company, in the midst of being acquired for $4.6 billion by Daiichi Sankyo, had filed 19 patent challenges in the US, but has settled five of these in the last two years.
-
Ranbaxy in a spot
about a month after the Japanese drug company, Daiichi Sankyo, acquired majority shares in Ranbaxy, India
-
US Cong seeks details of Ranbaxy drug approvals
Joe C Mathew / New Delhi July 24, 2008, 0:03 IST Two United States senators have asked the US Food and Drug Administration (USFDA) to provide details of market approvals given to all medicines sold by India's largest drug-maker Ranbaxy in that country. The senators, John Dingell and Bart Stupak, also want the FDA inspectors who were in charge of drug approvals for Ranbaxy to appear before a House of Representatives committee by the end of August.